View in EDS

Exceptional Response to Trastuzumab Deruxtecan in a Patient With Recurrent Ovarian Clear Cell Carcinoma With Human Epidermal Growth Factor Receptor 2 Expression.

Saved in:
Bibliographic Details
Title: Exceptional Response to Trastuzumab Deruxtecan in a Patient With Recurrent Ovarian Clear Cell Carcinoma With Human Epidermal Growth Factor Receptor 2 Expression.
Authors: Kong BL; Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Stommel JM; Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Keck JM; Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Kilburn D; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.; Division of Oncological Sciences Knight Cancer Institute, Oregon Health and Science University, Portland, OR., Streblow A; Oregon Health & Science University School of Medicine, Portland, OR., Egger J; Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Creason AL; Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Suciu CG; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.; Department of Diagnostic Radiology, Oregon Health & Science University, Portland, OR., Guimaraes AR; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.; Division of Oncological Sciences Knight Cancer Institute, Oregon Health and Science University, Portland, OR.; Department of Pathology, Oregon Health & Science University, Portland, OR., Corless CL; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.; Department of Diagnostic Radiology, Oregon Health & Science University, Portland, OR., Mills GB; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.; Division of Oncological Sciences Knight Cancer Institute, Oregon Health and Science University, Portland, OR., Pejovic TB; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
Source: JCO precision oncology [JCO Precis Oncol] 2024 Jun; Vol. 8, pp. e2300686.
Publication Type: Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38905574
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Exceptional Response to Trastuzumab Deruxtecan in a Patient With Recurrent Ovarian Clear Cell Carcinoma With Human Epidermal Growth Factor Receptor 2 Expression.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Kong+BL%22">Kong BL</searchLink>; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Stommel+JM%22">Stommel JM</searchLink>; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Keck+JM%22">Keck JM</searchLink>; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Kilburn+D%22">Kilburn D</searchLink>; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.; Division of Oncological Sciences Knight Cancer Institute, Oregon Health and Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Streblow+A%22">Streblow A</searchLink>; Oregon Health & Science University School of Medicine, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Egger+J%22">Egger J</searchLink>; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Creason+AL%22">Creason AL</searchLink>; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Suciu+CG%22">Suciu CG</searchLink>; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.; Department of Diagnostic Radiology, Oregon Health & Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Guimaraes+AR%22">Guimaraes AR</searchLink>; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.; Division of Oncological Sciences Knight Cancer Institute, Oregon Health and Science University, Portland, OR.; Department of Pathology, Oregon Health & Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Corless+CL%22">Corless CL</searchLink>; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.; Department of Diagnostic Radiology, Oregon Health & Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Mills+GB%22">Mills GB</searchLink>; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.; Division of Oncological Sciences Knight Cancer Institute, Oregon Health and Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Pejovic+TB%22">Pejovic TB</searchLink>; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101705370%22">JCO precision oncology</searchLink> [JCO Precis Oncol] 2024 Jun; Vol. 8, pp. e2300686.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Clinical+Oncology%22">American Society of Clinical Oncology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101705370 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2473-4284 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224734284%22">24734284 </searchLink><i>NLM ISO Abbreviation: </i>JCO Precis Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38905574
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1200/PO.23.00686
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e2300686
    Titles:
      – TitleFull: Exceptional Response to Trastuzumab Deruxtecan in a Patient With Recurrent Ovarian Clear Cell Carcinoma With Human Epidermal Growth Factor Receptor 2 Expression.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kong BL
      – PersonEntity:
          Name:
            NameFull: Stommel JM
      – PersonEntity:
          Name:
            NameFull: Keck JM
      – PersonEntity:
          Name:
            NameFull: Kilburn D
      – PersonEntity:
          Name:
            NameFull: Streblow A
      – PersonEntity:
          Name:
            NameFull: Egger J
      – PersonEntity:
          Name:
            NameFull: Creason AL
      – PersonEntity:
          Name:
            NameFull: Suciu CG
      – PersonEntity:
          Name:
            NameFull: Guimaraes AR
      – PersonEntity:
          Name:
            NameFull: Corless CL
      – PersonEntity:
          Name:
            NameFull: Mills GB
      – PersonEntity:
          Name:
            NameFull: Pejovic TB
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: 2024 Jun
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 2473-4284
          Numbering:
            – Type: volume
              Value: 8
          Titles:
            – TitleFull: JCO precision oncology
              Type: main
ResultId 1